Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C

Journal of Hepatology

Volumn 55, Issue 3, 2011, Pages 554-563

  Manns, Michael ^a   Zeuzem, Stefan ^b   Sood, Ajit ^c   Lurie, Yoav ^d   Cornberg, Markus ^a   Klinker, Hartwig ^e   Buggisch, Peter ^f   Rössle, Martin ^g   Hinrichsen, Holger ^h   Merican, Ismail ⁱ   Ilan, Yaron ^j   Mauss, Stefan ^k   Abu Mouch, Saif ^l   Horban, Andryes ^m   Müller, Thomas H ⁿ   Welsch, Christoph ^b   Chen, Rongdean ^o   Faruqi, Rab ^o   Pedicone, Lisa D ^o   Wedemeyer, Heiner ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f Ifi Institute   (Germany)

^g Center for Ambulatory Gastroenterology and Endocrinology   (Germany)

^h Practice for Gastroenterology and Hepatology   (Germany)

ⁱ Selayang Hospital   (Malaysia)

^j HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^k Center for HIV and Hepatogastroenterology   (Germany)

^l HILLEL YAFFE MEDICAL CENTER   (Israel)

^m MEDICAL UNIVERSITY OF WARSAW   (Poland)

ⁿ UNIVERSITY OF MUNICH   (Germany)

^o MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Asians; Drug therapy; Hepatitis C; Noninferiority; Randomized controlled trial; Whites

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ETHNICITY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLUENZA; INJECTION SITE ERYTHEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; WEIGHT REDUCTION;

ADULT; BODY WEIGHT; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTENTION TO TREAT ANALYSIS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TIME FACTORS;

EID: 84860390172     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.12.024     Document Type: Article

References (17)

1. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
2. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
3. A. Mangia, R. Santoro, N. Minerva, G.L. Ricci, V. Carretta, and M. Persico Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 N Engl J Med 352 2005 2609 2617 (Pubitemid 41007847)
4. P.J. Pockros, R. Carithers, P. Desmond, D. Dhumeaux, M.W. Fried, and P. Marcellin Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial Am J Gastroenterol 99 2004 1298 1305 (Pubitemid 39062267)
5. M. Lagging, N. Langeland, C. Pedersen, M. Farkkila, M.R. Buhl, and K. Morch Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection Hepatology 47 2008 1837 1845 (Pubitemid 351945551)
6. M. von Wagner, M. Huber, T. Berg, H. Hinrichsen, J. Rasenack, and T. Heintges Peginterferon-alpha-2a (40 kDa) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C Gastroenterology 129 2005 522 527 (Pubitemid 41096640)
7. O. Dalgard, K. Bjoro, H. Ring-Larsen, E. Bjornsson, M. Holberg-Petersen, and E. Skovlund Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response Hepatology 47 2008 35 42 (Pubitemid 351171039)
8. M.L. Shiffman, F. Suter, B.R. Bacon, D. Nelson, H. Harley, and R. Sola Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 N Engl J Med 357 2007 124 134 (Pubitemid 47057730)
9. M.P. Manns, S. Meyer, and H. Wedemeyer The German network of excellence for viral hepatitis (Hep-Net) Hepatology 38 2003 543 544 (Pubitemid 37052139)
10. J.L. Dienstag, and J.G. McHutchison American Gastroenterological Association technical review on the management of hepatitis C Gastroenterology 130 2006 231 264 (Pubitemid 43049856)
11. D.B. Strader, T. Wright, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147 1171 (Pubitemid 38428955)
12. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
13. J.G. McHutchison, E.J. Lawitz, M.L. Shiffman, A.J. Muir, G.W. Galler, and J. McCone Peginterferon alfa-2b or alfa-2a with ribavarin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
14. B. Willems, S.J. Hadziyannis, T.R. Morgan, M. Diago, P. Marcellin, and D. Bernstein Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without rapid virological response? J Hepatol 46 2007 S6
15. I.M. Jacobson, R.S. Brown Jr., B. Freilich, N. Afdhal, P.Y. Kwo, and J. Santoro Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial Hepatology 46 2007 971 981 (Pubitemid 350144761)
16. A. Mangia, N. Minerva, D. Bacca, R. Cozzolongo, E. Agostinacchio, and F. Sogari Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection Hepatology 49 2009 358 363
17. M.L. Shiffman, J. Salvatore, S. Hubbard, A. Price, R.K. Sterling, and R.T. Stravitz Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha Hepatology 46 2007 371 379 (Pubitemid 47344771)